Compare Amgen, Inc. (AMGN) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Kinder Morgan Inc — how do they compare? Amgen, Inc. trades at $416.99 (market cap $224.14B), while Kinder Morgan Inc trades at $31.75 (market cap $70.10B). The key difference: Amgen, Inc. is far larger — about 3.2× Kinder Morgan Inc's market cap, and Kinder Morgan Inc pays the higher dividend (3.75%). Which is the better fit depends on your goals.
| AMGN | KMI | |
|---|---|---|
Market Cap | $224.14B | $70.10B |
Sector | Health | Energy |
52-Week High | $417.20 | $34.31 |
52-Week Low | $271.18 | $25.84 |
Enterprise Value | $267.45B | $102.15B |
Dividend Yield | 2.43% | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
KMI trades at $31.70, up 0.99% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates, and raised full-year guidance. Recent news highlights a $5 billion joint venture for the Western Gateway Pipeline, signaling growth in natural gas infrastructure. Fundamentals show solid revenue growth, with 2025 revenue at $16.94 billion and net income margin improving to 19.31%.
The outlook is positive due to contracted cash flows and a robust project pipeline, but risks include high debt levels and exposure to energy market volatility. Analyst sentiment is mixed, with a near-even split between buy and hold ratings. The stock offers a dividend yield supported by stable cash generation, though valuation multiples like a P/E of 20.31 may limit near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
